In Brief: Positron
This article was originally published in The Gray Sheet
Executive Summary
Positron: President and CEO Werner Haas, PhD, resigns, the firm announced in an April 11 release. Chairman of the Board Gary Wood has assumed Haas' duties. The Houston firm is "currently experiencing liquidity problems" and "has recently been unable to pay certain of its obligations within their standard payment date," according to the release. Additionally, Positron's pending acquisition of GE Medical Systems' positron emission tomography assets ("The Gray Sheet" July 22, 1996, I&W-5) has been "delayed." Although the two firms remain in negotiations over the deal, GEMS is free to negotiate with other companies because the transaction did not close by March 31, Positron notes...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.